Histopathology Slide: Glioblastoma (IDH-Wildtype, WHO Grade 4)
Clinical correlate: Most common primary malignant brain tumor in adults, typically presenting in the 6th-7th decade with headache, seizures, focal neurologic deficits, and raised intracranial pressure. On imaging, a ring-enhancing lesion with central necrosis, often crossing the corpus callosum ("butterfly glioma").
Gross Appearance
- Poorly demarcated, infiltrating mass, often in the cerebral white matter (frontal/temporal lobes) with extension into gray matter and across the corpus callosum.
- Variegated cut surface: areas of yellow necrosis, hemorrhage, and cystic softening admixed with firmer tumor tissue - historically the basis for the older name "glioblastoma multiforme."
Low Power
- Highly cellular, infiltrative glial tumor with marked nuclear pleomorphism and geographic/serpiginous zones of necrosis.
- Necrotic zones are irregular, serpentine ("serpiginous") pale-pink anucleate areas.
- Tumor hypercellularity is concentrated along the edges of necrosis.
High Power - Key Diagnostic Features
- Pseudopalisading necrosis: Tumor cell nuclei line up densely around the anucleate necrotic zones, giving a "palisaded" appearance around geographic necrosis - considered a histologic hallmark of glioblastoma.
- Microvascular proliferation: Glomeruloid tufts of proliferating endothelial cells and pericytes, resembling renal glomeruli, seen at the tumor periphery - reflects the marked angiogenic drive of this tumor (VEGF-mediated).
- Cellular pleomorphism: Marked variation in cell and nuclear size and shape, with hyperchromatic, often bizarre nuclei; multinucleated tumor giant cells may be seen.
- Mitotic activity: Brisk, with frequent and sometimes atypical mitoses.
- Background: Infiltrating astrocytic tumor cells with fibrillary cytoplasmic processes merging into adjacent brain parenchyma (making complete resection essentially impossible).
Diagnostic Criteria (per current WHO classification)
A diffuse IDH-wildtype astrocytic tumor is graded as Glioblastoma, IDH-wildtype, WHO grade 4 if it shows:
- Microvascular proliferation, or
- Necrosis, or
- One or more of three molecular alterations even in their absence: TERT promoter mutation, EGFR gene amplification, or combined whole chromosome 7 gain / whole chromosome 10 loss (+7/-10)
This means a tumor can be designated glioblastoma grade 4 purely on molecular grounds even without classic necrosis or microvascular proliferation on histology.
Immunohistochemistry / Ancillary Studies
- GFAP: Positive, confirming astrocytic/glial lineage (though can be patchy in poorly differentiated areas).
- IDH1 R132H: Negative (by definition of IDH-wildtype glioblastoma; a positive result should prompt reclassification as IDH-mutant astrocytoma).
- Ki-67/MIB-1: High proliferative index, consistent with high-grade malignancy.
- ATRX/p53: Variable; helps distinguish from IDH-mutant astrocytomas which typically show ATRX loss and p53 overexpression.
- MGMT promoter methylation status: Not a diagnostic histologic feature but clinically essential - methylated MGMT predicts better response to temozolomide.
Key Differentials
| Feature | Glioblastoma | Anaplastic Astrocytoma (Gr.3) | CNS Lymphoma | Metastatic Carcinoma |
|---|
| Necrosis | Present (pseudopalisading) | Absent | Can have necrosis | Often present |
| Microvascular proliferation | Present | Absent | Absent | Absent |
| GFAP | Positive | Positive | Negative | Negative |
| Border with brain | Infiltrative, indistinct | Infiltrative | Can be discrete | Often well-demarcated |
One-line Summary for the Slide Label
"Glioblastoma, IDH-wildtype (WHO grade 4): highly cellular infiltrating glial neoplasm with marked nuclear pleomorphism, brisk mitoses, geographic necrosis with pseudopalisading tumor cells at the margins, and glomeruloid microvascular proliferation; GFAP-positive, IDH1 R132H-negative."
- Robbins & Cotran Pathologic Basis of Disease, 10th ed., p. 830-842 (Fig. 28.48)
- Robbins & Kumar Basic Pathology, p. 2072-2085 (Fig. 21.31)
- Goldman-Cecil Medicine, p. 3899
Note: No systematic reviews from the last 3 years contradict this core histologic/diagnostic framework - the WHO 2021 molecular criteria described above remain current (recent literature, e.g., PMID 41308410, focuses on AI-assisted diagnostics layered on top of this same histologic/molecular foundation, not a change to it).